Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Kymera Therapeutics (KYMR) over the last 4 years, with Q2 2025 value amounting to $40.0 million.

  • Kymera Therapeutics' Receivables - Net changed N/A to $40.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $40.0 million, marking a year-over-year change of. This contributed to the annual value of $15.0 million for FY2023, which is N/A changed from last year.
  • As of Q2 2025, Kymera Therapeutics' Receivables - Net stood at $40.0 million.
  • Kymera Therapeutics' Receivables - Net's 5-year high stood at $40.0 million during Q2 2025, with a 5-year trough of $900000.0 in Q1 2021.
  • Moreover, its 3-year median value for Receivables - Net was $15.0 million (2023), whereas its average is $18.6 million.